Protagonist Therapeutics, Inc.
A biotechnology company that designs oral and injectable peptide drugs for chronic conditions like psoriasis, blood disorders, and obesity. Founded in 2006 on peptide technology from the University of Pennsylvania, it was incubated in Australia before moving to California. Its name was chosen to suggest a central role in peptide medicine, and its psoriasis pill Icotyde is licensed to Johnson & Johnson.
Bought 583.3K
Bought 583.3K · Sold 336.7K
Bought 583.3K
Bought 583.3K
Bought 583.3K
Granted 1.11M · Bought 30.0K · Sold 619.4K
Granted 354.3K · Bought 30.0K · Sold 127.6K
Granted 224.4K · Sold 139.8K
Granted 72.8K · Bought 12.0K · Sold 24.0K
Granted 201.8K · Sold 43.8K
Granted 43.8K · Bought 18.0K · Sold 59.1K
Granted 216.4K · Sold 151.5K
Granted 40.8K · Sold 14.2K
Granted 35.1K · Sold 8.0K
Granted 15.0K · Bought 1.2K
Granted 14.5K
Granted 115.8K · Sold 108.0K
Granted 25.8K · Sold 18.0K
Granted 7.8K
Granted 8.4K · Sold 8.4K
Granted 2.5K · Sold 2.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Papanek JulieDirector · 2 transactions | — | 2.45Mas of Aug 2016 | — | 583.3K | — |
| Canaan X L.P. +1 co-filer10% owner · 15 transactions | — | 2.12Mas of May 2018 | — | 583.3K | 336.7K |
| Johnson & Johnson +1 co-filer10% owner · 3 transactions | — | 1.87Mas of Aug 2016 | — | 583.3K | — |
| Hall Steven Edward +3 co-filers10% owner · 4 transactions | — | 837.4Kas of Aug 2016 | — | 583.3K | — |
| Shanafelt ArmenDirector, 10% owner · 4 transactions | — | 837.4Kas of Aug 2016 | — | 583.3K | — |
| Patel Dinesh V PH DPresident and CEO, Director · 89 transactions | — | 598.5K | 1.11M | 30.0K | 619.4K |
| Gupta SuneelChief Development Officer · 21 transactions | — | 267.4Kas of Nov 2024 | 354.3K | 30.0K | 127.6K |
| Molina Arturo MDChief Medical Officer · 32 transactions | — | 99.1K | 224.4K | — | 139.8K |
| Selick Harold EDirector · 10 transactions | — | 84.8K | 72.8K | 12.0K | 24.0K |
| Liu David YChief R&D Strategy Officer · 34 transactions | — | 80.9Kas of Nov 2022 | 201.8K | — | 43.8K |
| Giraudo BryanDirector · 10 transactions | — | 64.5K | 43.8K | 18.0K | 59.1K |
| Ali AsifChief Financial Officer · 34 transactions | — | 59.0K | 216.4K | — | 151.5K |
| Shames Richard S.Chief Medical Officer · 13 transactions | — | 32.0Kas of Mar 2019 | 40.8K | — | 14.2K |
| O'Neil Thomas P.Chief Financial Officer · 5 transactions | — | 30.6Kas of Aug 2018 | 35.1K | — | 8.0K |
| Kalkofen Donald A.Chief Financial Officer · 4 transactions | — | 18.5Kas of Feb 2022 | 15.0K | 1.2K | — |
| Saks Samuel RChief Medical Officer · 2 transactions | — | 14.0Kas of Feb 2021 | 14.5K | — | — |
| Waddill William D.Director · 26 transactions | — | 7.8K | 115.8K | — | 108.0K |
| Williams Lewis TDirector · 4 transactions | — | 7.8K | 25.8K | — | 18.0K |
| O'Dowd Sarah ADirector · 2 transactions | — | 7.8K | 7.8K | — | — |
| Noonberg Sarah B.Director · 5 transactions | — | 0as of Feb 2021 | 8.4K | — | 8.4K |
| Khosla Chaitan PHDDirector · 2 transactions | — | 0as of Aug 2020 | 2.5K | — | 2.5K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +1.35M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.